ReviewReviews in cardiovascular medicine2025
Advancements in Pulmonary Embolism Management: Current Approaches and Future Directions.
Review in Reviews in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Catheter-directed thrombolysis versus anticoagulation for intermediate-risk and high-risk pulmonary embolism: a systematic review and meta-analysis.Open heart · 2026Pooled it
- Interventional Management of Intermediate-High-Risk Pulmonary Embolism: Current Evidence, Patient Selection and Personalised Treatment Strategies.Journal of clinical medicine · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pulmonary embolism (PE) is one of the leading causes of cardiovascular mortality, with a high 30-day mortality rate. Despite clear treatment guidelines based on patient risk profiles, evidence suggests a discrepancy between clinical practice worldwide and the recommendations outlined in these guidelines. This deviation is often due to the comorbidities present in patients with PE, which complicate management decisions. As a result, alongside traditional standard-of-care treatments, novel emerging therapies are being explored to address these challenges. This review aims to provide an overview of the current epidemiology, initial assessment strategies, conventional treatment options, and emerging therapeutic approaches for PE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.